GENUS is a generic drug manufacturer focused on Metabolic, Oncology. Key products include POKONZA.
GENUS's Key Drugs
GENUS's core commercial portfolio centers on POKONZA, spanning Metabolic and Oncology — its most strategically important drugs approved in the last 15 years.
GENUS's Recent FDA Approvals
New NDA/BLA approvals for GENUS over the last two years — novel drugs only, excluding generics and label supplements.
GENUS's Therapeutic Areas
GENUS's approved drugs and pipeline span 2 therapeutic areas, led by Metabolic and Oncology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GENUS's Top Competitors
GENUS's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
GENUS Pipeline Snapshot
GENUS has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • POKONZA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling